Literature DB >> 7629220

Clinical review 72: diagnosis and management of functioning islet cell tumors.

R R Perry1, A I Vinik.   

Abstract

Functional islet cell tumors cause recognizable clinical syndromes based on the peptide products they secrete (Table 1). Frequently, the diagnosis of these tumors is delayed. A high index of suspicion coupled with the use of appropriate biochemical and provocative tests should lead to earlier diagnosis. A suggested management plan for patients suspected of having an islet cell tumor is shown in Fig. 1. Earlier diagnosis coupled with advances in preoperative and intraoperative localization techniques have resulted in an increased number of patients being cured.

Entities:  

Mesh:

Year:  1995        PMID: 7629220     DOI: 10.1210/jcem.80.8.7629220

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization?

Authors:  Johann Dréanic; Céline Lepère; Mostafa El Hajjam; Hervé Gouya; Philippe Rougier; Romain Coriat
Journal:  Ther Adv Med Oncol       Date:  2016-07-05       Impact factor: 8.168

2.  Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.

Authors:  Naris Nilubol; Esther M Freedman; Martha M Quezado; Dhaval Patel; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2016-09-01       Impact factor: 5.958

3.  Surgical treatment of persistent hyperinsulinemic hypoglycemia (PHH) (insulinoma and nesidioblastosis).

Authors:  Daniel Casanova; Manuel G Polavieja; Angel Naranjo; Fernando Pardo; Fernando Rotellar; Francisco Gonzalez; Cristina Luzuriaga; Sara Regaño; Julio Freijanes
Journal:  Langenbecks Arch Surg       Date:  2007-03-21       Impact factor: 3.445

4.  Insulinoma--experience from 1950 to 1995.

Authors:  M P Boukhman; J H Karam; J Shaver; A E Siperstein; Q Y Duh; O H Clark
Journal:  West J Med       Date:  1998-08

Review 5.  Pancreatic endocrine neoplasms: a current update on genetics and imaging.

Authors:  S Philips; S N Shah; R Vikram; S Verma; A K P Shanbhogue; S R Prasad
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

6.  Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.

Authors:  Walid Shaib; Kisha Mitchell; M Wasif Saif
Journal:  Yale J Biol Med       Date:  2010-03

7.  Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Authors:  Stephanie A C Halvorson; Erin Gilbert; R Samuel Hopkins; Helen Liu; Charles Lopez; Michael Chu; Marie Martin; Brett Sheppard
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

8.  Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Authors:  Thomas J Quinn; Ziqiang Yuan; Asha Adem; Rula Geha; Chakravarthy Vrikshajanani; Wade Koba; Eugene Fine; David T Hughes; Herbert A Schmid; Steven K Libutti
Journal:  Surgery       Date:  2012-10-24       Impact factor: 3.982

9.  Human Insulinomas: Clinical, Cellular, and Molecular Aspects.

Authors:  Paul Komminoth; Philipp U. Heitz; Jürgen Roth
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

Review 10.  Pancreatic VIPomas: subject review and one institutional experience.

Authors:  Amir A Ghaferi; Karen A Chojnacki; William D Long; John L Cameron; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.